鹭燕医药（002788）新增【AI医疗】概念

Core Viewpoint - Luyuan Pharmaceutical (002788) has added the "AI Medical" concept due to its development in three core AI medical application areas: intelligent diagnostic equipment, medical service intelligence upgrades, and drug traceability intelligence [1] Group 1: Company Overview - Luyuan Pharmaceutical's main business includes the distribution of pharmaceuticals, traditional Chinese medicine pieces, medical devices, and retail pharmacy chains [1] - The company is also associated with other concept sectors such as elderly care, artificial intelligence, smart healthcare, the Straits West Coast, and cold chain logistics [1] Group 2: Financial Performance - For the first three quarters of 2025, Luyuan Pharmaceutical reported a main revenue of 15.855 billion yuan, an increase of 2.87% year-on-year [1] - The net profit attributable to shareholders was 220 million yuan, a decrease of 14.64% year-on-year, while the net profit excluding non-recurring items was also 220 million yuan, down 15.14% year-on-year [1] - In the third quarter of 2025, the company achieved a single-quarter main revenue of 5.455 billion yuan, up 6.81% year-on-year, with a net profit attributable to shareholders of approximately 65.14 million yuan, a decline of 2.74% year-on-year [1] - The company's debt ratio stands at 74.98%, with an investment income of -10.8849 million yuan and financial expenses of 139 million yuan, while the gross profit margin is 6.96% [1]